What happens in the brain when someone has Parkinson's

Parkinson's disease damages nerve cells in a specific part of the brain called the substantia nigra, which sits deep in the midbrain. These nerve cells produce a chemical messenger called dopamine, which helps control movement, balance, and coordination. When Parkinson's destroys these cells — sometimes losing 50 to 60 percent of them before symptoms appear — the brain cannot make enough dopamine to send the signals muscles need.

The damage happens gradually over years. Nerve cells die or stop working, and the brain compensates for a while by using the dopamine it still has more efficiently. But once the loss crosses a threshold, the body can no longer mask the shortage, and tremor, stiffness, or slowness of movement becomes noticeable. The person may not realize cells have been dying for a decade or more before that first symptom shows up.

Scientists do not yet know exactly why these particular nerve cells die in Parkinson's. The leading theories involve a protein called alpha-synuclein, which accumulates inside nerve cells and damages them from within. Other factors — genetics, environmental exposure, aging, or a combination — may trigger or speed up this process, but no single cause has been proven.

Key Takeaways

  • Parkinson's destroys dopamine-producing nerve cells in the substantia nigra, a region deep in the brain that controls movement and balance.
  • Symptoms appear only after significant cell loss has already occurred, which is why the disease often goes unnoticed for years before diagnosis.
  • The buildup of a protein called alpha-synuclein inside nerve cells is believed to be central to the damage, though the exact cause remains unclear.
  • Dopamine loss explains why movement becomes slow, stiff, or shaky, but Parkinson's also affects other brain regions and chemicals, leading to mood, sleep, and cognitive changes.
  • Medications that increase dopamine or mimic its effects can reduce movement symptoms, but they do not stop the underlying nerve cell death.

How dopamine loss causes movement problems

Dopamine acts as a chemical messenger that tells muscles when and how to move. When dopamine levels drop, the brain struggles to initiate movement, coordinate smooth motion, and adjust posture. This is why people with Parkinson's experience the hallmark symptoms: tremor (shaking at rest), rigidity (stiffness in the limbs and neck), and bradykinesia (slowness of movement).

The loss of dopamine also disrupts the brain's ability to plan and execute sequences of movement. A person may freeze mid-step, struggle to start walking, or find that their movements become smaller and slower as they continue — a symptom called hypokinesia. Writing becomes smaller, speech becomes quieter, and facial expressions flatten because the muscles involved receive weaker signals.

Postural instability — difficulty balancing and maintaining upright posture — develops as the disease progresses and affects other brain regions beyond the substantia nigra. This is why falls become a serious risk in later stages, even though early Parkinson's primarily damages the dopamine system.

Why other brain regions are affected beyond dopamine

Although Parkinson's is defined by dopamine loss, the disease damages other brain regions and affects other chemical messengers as well. The locus coeruleus (which produces norepinephrine) and the raphe nuclei (which produce serotonin) also lose nerve cells. This explains why people with Parkinson's often experience depression, anxiety, sleep disturbances, and fatigue — symptoms that dopamine-boosting medications alone do not fully address.

Damage to the basal ganglia — a group of structures that includes the substantia nigra — disrupts circuits that filter and refine motor commands. Normally, the basal ganglia help the brain decide which movements to make and which to suppress. With Parkinson's, this filtering breaks down, contributing to tremor and the difficulty initiating movement.

As Parkinson's advances, damage spreads to the cerebral cortex and other regions, which can lead to cognitive decline, memory problems, and in some cases, dementia. This progression varies widely between individuals; some people maintain sharp thinking for decades, while others develop cognitive symptoms earlier.

How the disease progresses in the brain

Parkinson's does not damage all brain regions at once. Research suggests the disease may start in the gut or the olfactory nerve (smell) and gradually spread upward to the brain, though this theory is still being tested. Once in the brain, the damage typically begins in the substantia nigra and spreads outward over years or decades.

The rate of progression varies greatly. Some people experience slow change over 20 years; others decline more rapidly. Factors that influence speed include age at diagnosis (younger onset may progress differently), genetics, and possibly environmental exposures, but doctors cannot predict an individual's course with certainty.

Brain imaging studies show that the accumulation of alpha-synuclein protein follows a pattern, spreading from one region to connected regions. This may explain why symptoms evolve in a somewhat predictable order — movement problems first, then mood and sleep issues, then cognitive changes — though the timeline differs for each person.

What medications do and do not do

Levodopa (L-DOPA) and dopamine agonists are the main medications used to treat Parkinson's. They work by increasing dopamine levels in the brain or mimicking dopamine's effects on nerve cells. These drugs can significantly reduce tremor, stiffness, and slowness, allowing people to move more freely and maintain independence longer.

However, medications do not stop or slow the underlying nerve cell death. They manage symptoms by working around the dopamine shortage, but the disease continues to damage the brain. Over time, as more cells die, medications become less effective, and doses must increase or change. This is why Parkinson's symptoms eventually progress despite treatment.

Other medications target different brain chemicals — serotonin, norepinephrine, or acetylcholine — to address depression, sleep problems, or cognitive symptoms. But again, these treat the effects of brain damage, not the damage itself. Research into disease-modifying treatments that might slow or stop nerve cell death is ongoing, but no such treatment is yet available.

The role of alpha-synuclein and protein buildup

Inside the nerve cells of people with Parkinson's, a protein called alpha-synuclein clumps together into structures called Lewy bodies. These clumps accumulate inside the cell and are thought to poison the cell from within, eventually killing it. The buildup of alpha-synuclein is so consistent in Parkinson's that finding Lewy bodies in brain tissue after death is considered the definitive sign of the disease.

Scientists do not yet know why alpha-synuclein misfolds and clumps in some people and not others. Genetic mutations in the gene that codes for alpha-synuclein can cause early-onset Parkinson's, but most people with Parkinson's do not carry these mutations. Environmental toxins, head injury, or chronic inflammation may trigger misfolding in people with genetic susceptibility, but the exact mechanism remains unclear.

Much current research focuses on stopping alpha-synuclein from clumping or clearing it from cells before it causes damage. If successful, these approaches might slow or prevent nerve cell death, but they are not yet available as treatments.

How brain imaging reveals Parkinson's damage

Doctors cannot see Parkinson's damage directly in a living brain — diagnosis is based on symptoms and response to medication. However, specialized imaging can show the loss of dopamine-producing cells. PET scans and SPECT scans can measure dopamine activity and reveal the characteristic pattern of loss in the substantia nigra.

Standard MRI scans usually look normal in early Parkinson's because the dopamine loss is not visible on conventional imaging. As the disease progresses and affects other brain regions, MRI may show changes, but these are not specific to Parkinson's and are not used for diagnosis.

Brain imaging is most useful for research and for ruling out other conditions that mimic Parkinson's symptoms. In clinical practice, a neurologist diagnoses Parkinson's by observing movement problems and how the person responds to dopamine-boosting medication, not by imaging alone.

Frequently Asked Questions

Can Parkinson's damage be reversed if caught early?

No. Once dopamine-producing nerve cells die, they do not regenerate. Early diagnosis allows treatment to begin sooner, which can help manage symptoms and maintain function longer, but the underlying cell death cannot be reversed. Current medications work around the dopamine shortage rather than restoring lost cells.

Does everyone with Parkinson's develop dementia?

No. Many people with Parkinson's maintain normal thinking and memory for their entire lives. Cognitive decline occurs in some people, particularly those diagnosed at an older age or with a longer disease duration, but it is not inevitable. The rate and severity of cognitive changes vary widely.

Is Parkinson's inherited?

Genetics play a role, but most Parkinson's is not directly inherited. About 10 to 15 percent of people with Parkinson's have a family member with the disease. Specific genetic mutations can cause early-onset Parkinson's, but most people with Parkinson's do not carry these mutations and have no family history.

Why do symptoms get worse even when taking medication?

Medications increase dopamine or mimic its effects, but they do not stop nerve cells from dying. As more cells are lost over time, the brain has less capacity to respond to medication. Doses may need to increase, or new medications may be added, but the underlying disease continues to progress.

Can environmental factors cause Parkinson's?

Exposure to certain pesticides, herbicides, or heavy metals has been associated with increased Parkinson's risk in some studies, but no single environmental cause has been proven. Parkinson's likely results from a combination of genetic susceptibility and environmental or lifestyle factors, but the exact mix differs for each person.